Adaptive platform trial of conventional and emerging next-line artemisinin combination therapies for uncomplicated Plasmodium falciparum malaria in African children. (ADAPT-ACT)

Start Date15 Jun 2026

Sponsor / Collaborator

Medical University of Vienna

PACTR202511868232388

/ SuspendedPhase 4IIT

Efficacy and safety of artemisinin combination therapies for the treatment of uncomplicated Plasmodium falciparum malaria in children aged 6 months to 12 years living in Gabon

Start Date01 Nov 2025

Sponsor / Collaborator-

PACTR202509595165365

/ SuspendedPhase 4

Randomised controlled trial to assess the efficacy of artemisinin combination therapies in a setting of emerging artemisinin resistance in Uganda.

Start Date01 Oct 2025

Sponsor / Collaborator-

100 Clinical Results associated with Artemisinin

100 Translational Medicine associated with Artemisinin

100 Patents (Medical) associated with Artemisinin

7,485

Literatures (Medical) associated with Artemisinin

31 Dec 2026·Emerging Microbes & Infections

Asymptomatic malaria: a hidden reservoir for the transmission and circulation of artemisinin partial-resistant Plasmodium falciparum in Tanzania

Article

Author: Louis, Johnsy Mary ; Muh, Fauzi ; Mazigo, Ernest ; Todd, Jim ; Kwon, Tae-Hyung ; Han, Eun-Taek ; Lee, Wang-Jong ; Syahada, Jadidan Hada ; Park, Won Sun ; Lee, Kyu Joon ; Na, Sunghun ; Lu, Feng ; Kidima, Winifrida ; Manjurano, Alphaxard ; Fitriana, Fadhila ; Chun, Wanjoo ; Han, Joon-Hee ; Lee, Se Jin ; Han, Jin-Hee ; Nam, Joo-Won ; Jun, Hojong

Asymptomatic malaria infections contribute substantially to silent transmission, but the prevalence of artemisinin resistance (ART-R) markers in these carriers remains poorly understood. A community-based cross-sectional study was conducted in Tanzania from December 2022 to July 2023, enrolling 3,489 participants from high-transmission regions of Geita and Kigoma and a low-transmission region of Arusha. Four villages per region were randomly selected, and venous blood samples were tested using rapid diagnostic tests, microscopy, and qPCR, revealing overall positivity rate of 24.4%, 15.8%, and 26.2%, respectively, which indicate a significant proportion of submicroscopic infections. Among the 802 isolates successfully sequenced for pfk13 and pfmdr1, 24 (3.0%) isolates from high-transmission areas carried validated pfk13 partial-resistance markers Y493H (0.2%), R561H (2.0%), and A675V (0.7%), while all low-transmission isolates were wild-type. All isolates retained the pfmdr1 N86 codon, and the NFD haplotype associated with reduced susceptibility to lumefantrine was detected in 48.1% and 48.4% of isolates in high- and low-transmission areas, respectively. Mutations were more frequent in children under five and in females. Artemether-lumefantrine (AL, 64.7%) was the most commonly used antimalarial in high-transmission areas, whereas sulfadoxine-pyrimethamine (SP, 75.9%) predominated in low-transmission areas. Higher AL use correlated with increased pfmdr1 mutation prevalence in high-transmission regions, while NFD detection in low-transmission areas may reflect gene flow from high-transmission settings. These findings demonstrate that asymptomatic carriers are a substantial hidden reservoir of ART-resistant parasites, emphasizing the importance of integrating molecular surveillance and demographic information on asymptomatic infections into malaria control programs to detect emerging resistance and guide targeted interventions in Tanzania.

01 Dec 2026·MOLECULAR BIOLOGY REPORTS

Anticancer properties of Artemisia species: mechanisms and experimental evidence

Review

Author: Eshawesh, Eman ; Ebrahim, Fawzi ; Elzagheid, Adam ; Alshareef, Esam ; Abulayha, Abdulmunem M

The genus Artemisia (family Asteraceae) is widely recognized for its medicinal properties, among which artemisinin is the most notable, historically serving as a key antimalarial agent. Accumulating evidence now highlights the significant anticancer potential of Artemisia species, with bioactive compounds such as artemisinin and its derivatives exhibiting promising activity across multiple cancer types. This review provides a comprehensive overview of the molecular mechanisms underlying the anticancer effects of Artemisia-derived compounds, including apoptosis induction, cell cycle arrest, and oxidative stress modulation. In addition, it examines their therapeutic efficacy in preclinical in vivo models and summarizes findings from early-phase clinical trials. Despite encouraging preclinical results, challenges such as drug resistance, limited bioavailability, and barriers to clinical translation remain.

01 Dec 2026·FUNCTIONAL & INTEGRATIVE GENOMICS

Exploring the potential targets and mechanisms of artemisinin in the treatment of diabetic kidney disease using network pharmacology and molecular docking

Article

Author: Yu, Shuqin ; Cai, Xiangzeng ; Li, Hongning

Diabetic kidney disease (DKD) is a secondary glomerular disease caused by diabetes, and its incidence is increasing annually. Artemisinin is an organic compound with multiple pharmacological effects. This study aims to investigate the potential therapeutic effects of artemisinin on DKD and its molecular mechanisms. Common targets were identified using network pharmacology, transcriptome data from the Gene Expression Omnibus (GEO) database, and three machine learning algorithms, including Least Absolute Shrinkage and Selection Operator (LASSO), Support Vector Machine Recursive Feature Elimination (SVM-RFE), and Random Forest (RF). Target expression profiles were examined through single-cell sequencing data analysis. Molecular docking and cellular assays, including western blot, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL), enzyme-linked immunosorbent assay (ELISA), and reactive oxygen species (ROS) detection, validated the effects of artemisinin and Fms related receptor tyrosine kinase 1(FLT1) on human renal glomerular endothelial cells (HRGECs) under a high-glucose (HG) injury model. A total of 64 common targets between artemisinin and DKD were identified, and machine learning identified FLT1 as a key target. Single-cell analysis revealed high FLT1 expression in DKD endothelial cells. More importantly, artemisinin exhibited stable binding to FLT1. HG reduced FLT1 expression and cell viability in HRGECs. Besides, HG-induced decrease in cell viability, increase in proportion of TUNEL-positive cells, elevation in the levels of interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) and lipid ROS production were reversed by FLT1 overexpression or artemisinin treatment, and these protective effects of artemisinin were significantly attenuated upon FLT1 knockdown. Artemisinin alleviates HG-induced HRGEC injury by restoring FLT1 expression, providing a potential therapeutic target for DKD treatment.

News (Medical) associated with Artemisinin

06 Apr 2026

·www.prnewswire.com

ArtemiLife Nears Milestone in Landmark Prostate Cancer Clinical Trial

Phase 2 Trial of ArtemiCafé® Decaf at University of Kentucky Markey Cancer Center Approaches Completion CAMP HILL, Pa., April 6, 2026 /PRNewswire/ -- ArtemiLife, the innovator behind ArtemiCafé® Decaf, a commercially available decaffeinated coffee infused with a controlled dose of Artemisia annua, is pleased to announce that its groundbreaking Phase 2 clinical trial for prostate cancer maintenance is nearing its conclusion. Conducted in collaboration with the University of Kentucky's Markey Cancer Center, the trial has been investigating whether ArtemiCafé® Decaf can serve as a maintenance therapy to reduce and/or stabilize rising prostate-specific antigen (PSA) levels in men with biochemical recurrence of prostate cancer following localized treatment. Continue Reading Artemicafe Decaf products now available throughout the US. Biochemical recurrence, a rising PSA following surgery or radiation, affects an estimated 50–90% of men with high-risk prostate cancer and represents one of the most challenging and underserved gaps in oncology care. Following the successful completion of Phase 1 dose escalation clinical trials (NCT04805333), ArtemiLife and Markey Cancer Center researchers set out to explore whether a daily regimen of ArtemiCafé® Decaf, consumed as four cups per day over 24 weeks, could offer men in this situation a natural, tolerable, and integrative option to delay or avoid more aggressive intervention. The trial (NCT05478239) commenced patient enrollment in August 2023, with researchers monitoring PSA levels, testosterone, and key biomarkers of the NRF2/KEAP1 signaling pathway throughout the treatment period. As the trial approaches its final stages, ArtemiLife is building toward a full data readout and anticipates sharing results with the medical community. While specific outcomes cannot yet be disclosed, the company is proud of the rigor and depth of this collaboration with Markey Cancer Center, Kentucky's only NCI-designated Comprehensive Cancer Center. In tandem with this clinical milestone, ArtemiLife is pleased to announce the completion of a new production run of ArtemiCafé® Decaf. Fresh supply is now available for consumers who have come to rely on ArtemiCafé® as part of their daily wellness routine, as well as for new customers looking to integrate this science-backed product into their lives. Available throughout the United States at artemilife.com. Each batch of ArtemiCafé® Decaf is produced to exacting standards to deliver a consistent, controlled dose of Artemisia annua, the same formulation used in both Markey Cancer Center clinical trials. ArtemiCafé® Decaf is made from Artemisia annua, a plant with a centuries-long history in traditional medicine and best known as the source of artemisinin, the gold standard antimalarial compound. Emerging laboratory research has revealed that artesunate, a derivative of artemisinin, exhibits meaningful anti-tumor activity, including the ability to target androgen receptor pathways and reduce prostate cancer cell proliferation. The approaching conclusion of the prostate cancer trial is not an endpoint, it is a launching pad. ArtemiLife's next phase of its clinical mission includes expanding into: Breast Cancer — Exploring ArtemiCafé®'s potential role in maintenance therapy for breast cancer patients following standard treatment. Lung Cancer — Investigating whether Artemisia annua compounds may support outcomes in one of the most prevalent and deadly cancers globally. Preventive Applications — Evaluating the role of regular consumption of ArtemiCafé® as a proactive health tool in cancer-prevention contexts. Expanded Product Development — Scaling ArtemiLife's product line to meet growing consumer and clinical demand. Results of the ovarian cancer Phase 1 clinical trial, revealed promising safety and tolerability findings that were presented at the Society of Gynecologic Oncology annual meeting in Seattle in 2025, demonstrating ArtemiLife's ability to move fluidly across cancer types with a single, accessible product. That momentum now positions the company for broader clinical investment. "We are at a pivotal moment," said Adam Maust, CEO of ArtemiLife. "Our mission has always been to support scientific advances through a product that fits seamlessly into people's daily lives. As we conclude this prostate trial we look forward to continuing the movement that is redefining how we think about cancer maintenance, one cup at a time." About ArtemiLife: ArtemiLife is a health and wellness company founded on the mission of helping people take control of their well-being. The company's flagship product, ArtemiCafé® Decaf, is the only commercially available coffee containing a controlled dose of Artemisia annua. ArtemiLife collaborates with the University of Kentucky's Markey Cancer Center on oncology research and sources all Artemisia annua from Kentucky farms. For more information, visit . SOURCE ArtemiLife 21% more press release views with Request a Demo

Phase 1Phase 2ASCO

19 Feb 2026

·www.fiercepharma.com

Manus Bio scores $15M US contract for domestic supply of flu drug component

“Rather than replicating outdated foreign manufacturing practices, we’re deploying next-generation American technology,” Christine Santos, Manus Bio's chief technology officer, said in a statement. Synthetic biology specialist Manus Bio has scored a $15 million contract from the U.S. government to create a domestic supply source for shikimic acid, a key starting material used in the production of influenza drug Tamiflu. The agreement comes by way of the Administration for Strategic Preparedness and Response (ASPR), part of the Department of Health and Human Services (HHS), which is working to bolster the U.S.' pharmaceutical supply chain as a national security matter. The ASPR funding will help Manus add another large-scale fermentation line at its Augusta, Georgia, facility, the company said in a Feb. 18 press release. Manus estimates that more than 80% of the key ingredients for U.S. essential medicines are either produced or sourced from overseas, primarily in China and India.Shikimic acid is a key intermediate traditionally extracted from star anise that has been used to synthesize Tamiflu's active ingredient, oseltamivir. As it stands, the component is "sourced entirely from China," according to the ASPR. “Rather than replicating outdated foreign manufacturing practices, we’re deploying next-generation American technology,” Christine Santos, Manus' chief technology officer, said in a statement. “Using advanced biology and precision fermentation, we engineer microorganisms into highly efficient ‘cell factories’ that can produce critical bioalternative ingredients and inputs domestically," she explained. The deal comes on the heels of Manus receiving $32.4 million from the HHS' Defense Production Act Title III program in November 2024. Under that tie-up, Manus is teaming up with continuous flow chemistry specialist ArtemiFlow to help produce critical medicines at scale in the U.S. At the time, Manus noted that it would also expand its Augusta plant to add capabilities in key starting material and active pharmaceutical ingredient production. The first component slated for production on Manus and ArtemiFlow's combined platform was artemisinin, a key starting material for artesunate, an antiparasitic drug used to fight malaria, the companies previously said.

13 Nov 2025

·www.fiercebiotech.com

Novartis\' resistance-busting malaria drug GanLum hits phase 3 goal

Novartis plans to seek approval for GanLum, which has a fast track designation from the FDA, as soon as possible. \n A phase 3 trial of Novartis’ next-generation malaria treatment has met its primary endpoint, positioning the drugmaker to seek approval of a therapy with the potential to kill drug-resistant parasites.The World Health Organization (WHO) has sounded the alarm in recent years about the rise of partial resistance to artemisinin, the mainstay of malaria treatment in Africa. Researchers have found mutations linked to partial resistance in multiple regions of Africa. Some studies have reported higher levels of treatment failure. In 2022, the WHO hailed Novartis’ GanLum as the most promising non-artemisinin-based combination. The Swiss drugmaker validated the promise Wednesday evening by reporting that GanLum performed as well as the standard-of-care treatment Coartem.Investigators studied 1,688 adults and children across 34 sites in 12 African countries to assess the effect of GanLum, a combination of lumefantrine and the novel non-artemisinin antimalarial ganaplacide. The cure rate in people who took a sachet of GanLum granules daily for three days was 97.4% or 99.2%, depending on the analysis. The Coartem results were 94% and 96.7%, respectively. Those figures represent people who were free from clinical symptoms and baseline parasites 28 days after the start of treatment. Patients with new infections were included in the cure rate. Excluding those patients, Novartis reported cure rates of 85.3% for GanLum, compared to 82.1% for the standard of care. GanLum’s safety profile was similar to standard of care, according to the drugmaker.Novartis said additional analysis indicated GanLum was highly effective against mutant malaria parasites associated with partial drug resistance. The Swiss drugmaker also noted a rapid response against mature gametocytes, the sexual stage of the parasite’s life cycle responsible for onward transmission. GanLum showed high efficacy against multiple forms of the parasite, Abdoulaye Djimdé, Ph.D., professor of parasitology and mycology at the University of Science, Techniques and Technologies of Bamako, Mali, said in a statement. Novartis’ press release lacks a close look at how GanLum performed against the five parasitic Plasmodium species that infect humans. The drugmaker plans to seek approval for GanLum, which has a fast track designation from the FDA, as soon as possible. Novartis said the drug would represent the first major innovation in malaria treatment since it brought Coartem to market in 1999. While GanLum could mitigate the threat of artemisinin resistance, its use of lumefantrine leaves the drug combination exposed to another potential risk. Lumefantrine is used in Coartem. The WHO has said resistance to lumefantrine would represent a major setback in recent research and development efforts.

$Novartis\' resistance-busting malaria drug GanLum hits phase 3 goal$

Phase 3Clinical ResultFast Track

100 Deals associated with Artemisinin

External Link

KEGG	Wiki	ATC	Drug Bank
D02481	Artemisinin	P01BE01	DB13132

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Malaria	China	KPC Pharmaceuticals, Inc.	01 Jan 1991

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Cardiotoxicity	Preclinical	China	Southwest University (China)	19 May 2025
Polycystic Ovary Syndrome	Preclinical	China	Fudan University	14 Jun 2024
COVID-19	Preclinical	United States	Oncotelic Therapeutics, Inc.	04 Jul 2020
Alzheimer Disease	Preclinical	China	Nanjing Medical University	12 Feb 2013

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02802501 (200894, CTgov)	Phase 3	Malaria, Vivax	150	DHA-PQP (DHA-PQP Only)	lylmyogtor = yhdzkjjldy gbuugzikzz (wbuogerbfb, pdnrsovnqa - irotccwumn) View more	-	24 Jul 2020
				Tafenoquine+DHA-PQP (Tafenoquine+ DHA-PQP)	lylmyogtor = pxrxnnhcvn gbuugzikzz (wbuogerbfb, nmvwbnpbuz - brwvlttcjr) View more
Pubmed \| Clin Infect Dis	Phase 3	Malaria	176	Artemether-lumefantrine (AL)	aqtdvxylrr(wxwsrmsggb) = gtrjaoqqsb edarlgsirz (mxbsfsszkw )	-	01 Aug 2014
				Dihydroartemisinin-piperaquine (DP)	aqtdvxylrr(wxwsrmsggb) = reqhndxapg edarlgsirz (mxbsfsszkw )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis